Sugi Predict

Sugi Predict / Compounds / SCHEMBL532278

SCHEMBL532278

SCHEMBL532278

CS(=O)(=O)NCc1cccc(B(O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 2/20 0.51
▸ LPL P06858 2/20 0.47
▸ LIPG Q9Y5X9 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ KMT2A Q03164 1/20 0.45
▸ BRD4 O60885 1/20 0.44
▸ CYP19A1 P11511 6/20 0.43
▸ NFATC1 O95644 2/20 0.43
▸ PSMB5 P28074 2/20 0.42
▸ VCP P55072 1/20 0.41
▸ CXCR1 P25024 1/20 0.40
▸ CXCR2 P25025 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14830139 0.84 MGLL (0.50) ENPP2LIPGKDM4EPOLBTSHR
SCHEMBL957142 0.80 KMT2A (0.59) ENPP2LPLLIPGKDM4EPOLB
SCHEMBL5724799 0.78 CYP1A2 (0.55) ENPP2LIPGKDM4EPOLBTSHR
SCHEMBL3724201 0.78 ENPP2 (0.60) ENPP2LPLLIPGKDM4E
SCHEMBL27799067 0.77 BRD4 (0.44) KDM4EPOLBTSHRRECQLKMT2A
SCHEMBL23732879 0.76 KMT2A (0.41) ENPP2KDM4EPOLBTSHRRECQL
SCHEMBL13462548 0.76 CYP19A1 (0.51) KDM4EPOLBTSHRRECQLKMT2A
SCHEMBL8265344 0.76 CYP19A1 (0.56) KDM4EPOLBTSHRRECQLKMT2A
SCHEMBL27811793 0.76 CYP19A1 (0.51) KDM4EPOLBTSHRRECQLKMT2A
SCHEMBL955708 0.75 ENPP2 (0.53) ENPP2LPLLIPGKMT2APSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE UNIV MASARYKOVA (CZ) 2025-11-20 — — US disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
EP-4602046-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE Masarykova Univerzita (CZ) 2025-08-20 — — EP disclosed
WO-2024078649-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE MASARYKOVA UNIVERZITA (CZ) 2024-04-18 — — WO disclosed
EP-4353727-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE Masarykova Univerzita (CZ) 2024-04-17 — — EP disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
CN-117120429-A KHK inhibitor 吉利德科学公司 2023-11-24 — — CN disclosed
US-20220340577-A1 GCN2 INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2022-10-27 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
WO-2008073785-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-06-19 — — WO disclosed
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PLRAMED LIMITED (GB) 2008-02-14 — — US disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 — — WO disclosed
US-20070270415-A1 Benzothiadiazine compounds LESLABORATOIRES SERVIER (FR) 2007-11-22 — — US disclosed
WO-2007127183-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GENENTECH, INC. (US) 2007-11-08 — — WO disclosed
US-7268130-B2 Benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2007-09-11 — — US disclosed
EP-1812439-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-08-01 — — EP disclosed
US-20060094712-A1 New benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2006-05-04 — — US disclosed
WO-2006044687-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-04-27 — — WO disclosed
US-20060084650-A1 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084650-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ENPP2 1660/4885LPL 1857/4885LIPG 837/4885
US-20070270415-A1 Benzothiadiazine compounds SLC1A1, SLC1A2, SULT2A1 ENPP2 1465/4885LPL 4639/4885LIPG 4528/4885
US-20080039459-A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use PIK3CA, PI4KB, PI4KA ENPP2 976/4885LPL 1210/4885LIPG 733/4885
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE FLT3, ROS1, MAP4K2 ENPP2 1040/4885LPL 4726/4885LIPG 3782/4885
US-20060094712-A1 New benzothiadiazine compounds SLC1A1, SLC1A2, GABRA5 ENPP2 1094/4885LPL 4630/4885LIPG 4471/4885
US-20220340577-A1 GCN2 INHIBITORS AND USES THEREOF EIF2AK4, GCN1, GCGR ENPP2 236/4885LPL 589/4885LIPG 1492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.